A novel insight of sentinel lymph node concept based on 1-3 positive nodes in patients with pT1-2 gastric cancer.
BACKGROUND
Sentinel node (SN) biopsy has been practiced in gastric cancer in recent years, and many studies focused on the distribution of solitary lymph node metastasis (SLM) to assess the pattern of SN. In fact, there is usually more than one SN existing in gastric cancer. The distribution of SNs needs to be further re-evaluated.


METHODS
A total of 289 patients in pT1-2 stage with 1-3 positive nodes confined to same compartment were included in this study with informed consents. The primary lesion was solitary (≤ 5.0 cm in diameter) and D2 or D3 lymph node dissection had been performed. The location of metastatic lymph nodes was analyzed retrospectively.


RESULTS
Most positive nodes occurred in N1 compartment, with frequency of 79.6% to 85.7% based on site of tumor. In the lower third of stomach, no. 6 was the most common metastatic site and no. 3 was the second; the order was reversed for SLM. With increasing depth of tumor invasion, a progressively augmented nodal involvement was shown. Nearly a half appeared transverse metastasis when the tumor located at the lesser or greater curvature. Among skip metastasis, no. 7, 8a, 9 and 11p were the most common metastatic sites and the prognosis was as similar as that of patients with N1 involved only.


CONCLUSIONS
The 1-3 positive nodes in the same compartment should be possible SNs, and most of which are restricted in N1 in pT1-2 gastric cancer. Transversal and 2 stations lymph node metastasis are common.
Department of Surgical Oncology, the First Hospital of China Medical University, Shenyang 110001, PR China.
Baojun
B
Huang
Zhenning
Z
Wang
Zhe
Z
Sun
Bo
B
Zhao
Huimian
H
Xu
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D005743:Gastrectomy; D006801:Humans; D053208:Kaplan-Meier Estimate; D016015:Logistic Models; D008198:Lymph Nodes / Q000473:pathology*; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D021701:Sentinel Lymph Node Biopsy / Q000379:methods*; D013274:Stomach Neoplasms / Q000473:pathology* / Q000601:surgery
World J Gastroenterol. 2007 Sep 21;13(35):4776-80
17729400
Ann Surg Oncol. 2000 Apr;7(3):210-7
10791852
J Gastrointest Surg. 2007 Sep;11(9):1146-53
17576611
Hepatogastroenterology. 2007 Sep;54(78):1882-6
18019740
J Surg Oncol. 2009 Mar 1;99(3):137-42
19117015
Surg Clin North Am. 2000 Dec;80(6):1799-809
11140874
Anticancer Res. 2005 Mar-Apr;25(2B):1349-52
15865090
Surg Today. 1999;29(8):695-700
10483741
Lancet Oncol. 2008 Mar;9(3):279-87
18308253
Br J Surg. 2002 Nov;89(11):1435-7
12390388
Clin Cancer Res. 2004 Oct 15;10(20):6912-8
15501969
CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96
18287387
Surgery. 2007 Jun;141(6):757-63
17560252
World J Gastroenterol. 2006 Jan 21;12(3):354-62
16489633
Eur J Surg Oncol. 2003 Dec;29(10):895-9
14624784
ANZ J Surg. 2005 Aug;75(8):645-9
16076325
Ann Surg. 2009 Jan;249(1):58-62
19106676
Hepatogastroenterology. 2002 Sep-Oct;49(47):1449-52
12239964
Am J Surg. 2003 Jul;186(1):23-7
12842743
J Gastrointest Surg. 2008 Mar;12(3):550-4
17786527
Gastric Cancer. 2004;7(3):149-53
15449202
World J Surg. 2002 Mar;26(3):318-22
11865368
Gastric Cancer. 2005;8(2):103-10
15864717
Ann Surg Oncol. 2002 Mar;9(2):192-6
11888878
World J Surg. 2009 Jun;33(6):1235-9
19288280
Ann Surg. 2006 Mar;243(3):341-7
16495698
Gastric Cancer. 1998 Dec;1(1):10-24
11957040